Changes to Section 10.4.2 Statistical hypothesis, model, and method of analysis
This section was amended as follows
The null hypothesis of no difference in GFR at Month 6 between both treatment groups H0: μCertican = μControl will be tested against the two-sided alternative hypothesis of different mean GFR at Month 6 of the Certican® compared to control regimen H1: μCertican ≠ μControl µ indicates the mean GFR at Month 6.
The hypotheses will be tested exploratively with an analysis of covariance (ANCOVA) with treatment, center, and occurrence of rejections before randomization as factors, and GFR at Visit 3 (Baseline 2) as covariate. Raw as well as adjusted means (= LS-means, LS: least square means) will be presented for the treatment contrast together with its confidence interval and a two-sided p-value. The significance level will be 5% (two-sided). The full analysis set (FAS) will be used for the primary analysis. There are no multiplicity issues to be addressed since only the hypothesis of superior efficacy of the Certican® vs. the control regimen will be tested confirmatorily.
Changes to Section 10.7 Sample size calculation
The section was amended by adding the following sentence:
From data for the subgroup of elderly patients in study CRAD001A2418, the probable difference in the GFR (Cockcroft-Gault) between the CNI-free regimen group and the standard regimen group is estimated as δ = 8 ml/min with a standard deviation of 16 ml/min at Month 6 after transplantation. Assuming a difference in the mean GFR of 8 ml/min (60 ml/min in the CNI-free group and 52 ml/min in the standard regimen group) and a common standard deviation of 19 ml/min, a two-group t-test with a 5% two-sided significance level will have 80% power to detect this difference when the sample sizes in the CNI-free group is 135 and in the standard regimen group is 68, respectively (a total sample size of 203). Taking into account a common drop-out rate of 10%, 162 patients need to be randomized into the CNI-free group, and 82 into the standard regimen group (a total drop-out adjusted sample size of 244 patients). Enrollment will be continued until the required sample size will be achieved. Due to slow recruiting it was determined that the planned sample size of 240-260 patients cannot be achieved. Thus, enrollment will be terminated with 74 randomized patients.
